Trial Profile
A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms EMPOwER; Global EMPOwER
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 26 Apr 2022 Results analyzing the effects of erenumab on PROs assessing function and quality-of-life outcomes after 3 months of treatment, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 25 Jun 2021 Primary endpoint (Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP)) has been met as per results published in the Cephalalgia
- 25 Jun 2021 Results published in the Cephalalgia